Previous 10 | Next 10 |
Gainers: Ever-Glory International Group (NASDAQ:EVK) +122%. Infinity Pharmaceuticals (NASDAQ:INFI) +33%. Exicure (NASDAQ:XCUR) +34%. Xenetic Biosciences (NASDAQ:XBIO) +31%. Atlas Technical Consultants (NASDAQ:ATCX) +28%. Annovis Bio (NYSE:ANVS) +22%. Full Truck Alliance (NYSE:YMM) +21%. Allie...
Exicure Inc. (NASDAQ: XCUR) and Ipsen have signed an exclusive collaboration agreement to research, develop and commercialize novel Spherical Nucleic Acid as potential investigational treatments for Huntington’s disease and Angelman syndrome. Philippe Lopes-Fernan...
Gainers: Exicure (NASDAQ:XCUR) +38%, Infinity Pharmaceuticals (NASDAQ:INFI) +26%, Ra Medical Systems (NYSE:RMED) +22%, Galmed Pharmaceuticals (NASDAQ:GLMD) +22%, Lava Therapeutics (NASDAQ:LVTX) +18%. Losers: TG Therapeutics (NASDAQ:TGTX) -24%,...
Ever-Glory EVK +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Moderna sign Option and License Agr...
Ipsen obtains exclusive options to Spherical Nucleic Acids (SNAs™) currently under discovery evaluation for Huntington’s disease and Angelman syndrome Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exerci...
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory drugs utilizing spherical nucleic acid (SNA™) technology, will host a virtual R&D Day on Thursday, July 15, 2021 from 10:00 am to 11:00 am ET. The event will showcase Exicure’s neuroscience pipeline, including ...
Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will present a company update as well as participate in a series of 1x1 meetings at the L...
Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will participate in the following upcoming conferences: BIO Digital 2021 Form...
Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately. ...
— Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs — Exicure, Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA&...
News, Short Squeeze, Breakout and More Instantly...
Shares of Ooma, Inc. (NYSE:OOMA) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter fina...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 121.3% to $0.3941 on volume of 248,629,940 shares Sharps Technology Inc. (STSS) rose 184.6% to $0.61 on volume of 114,390,080 shares Crown Electrokinetics Corp. (CRKN) rose 31.2% to $0.1325 on volume ...
Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEa...